+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comprehensive CADM1 promoter methylation analysis in NSCLC and normal lung specimens

Comprehensive CADM1 promoter methylation analysis in NSCLC and normal lung specimens

Lung Cancer 72(3): 316-321

Methylation-mediated silencing of the tumour suppressor CADM1 has been functionally linked to lung cancer development. We aimed to determine whether CADM1 promoter methylation is a candidate early detection marker for lung cancer. To this end frozen tissue samples of 36 non-small cell lung cancers, 26 corresponding tumour distant normal tissue samples as well as 6 samples of normal lung from non-lung cancer patients were tested for DNA methylation at three different regions within the CADM1 promoter (M1, M5 and M9) using methylation specific PCR followed by methylation specific reverse line blot analysis. Sixty-four percentage of tumour samples tested positive at the M1 region, 47% at M5 and 74% at the M9 region, compared with 65% (M1), 23% (M5) and 46% (M9) of paired normal tissue samples. Methylation of each of these promoter regions was also detected in the majority of non-lung cancer control samples. Dense methylation, defined as methylation at ≥2 promoter regions, was detected in 66% of tumour samples compared with 38% of paired normal tissues and 67% of non-lung cancer control samples. Within the small subgroup of female patients dense methylation was found in all tumour samples but only 22% of paired normal samples. Neither methylation of individual sites nor dense methylation was correlated with disease free survival. In conclusion, CADM1 promoter methylation is a frequent event in NSCLC as well as normal lung, both of lung cancer and non-lung cancer patients. Hence, CADM1 methylation analysis is unlikely to have diagnostic value for the early detection of lung cancer in an unselected population. However, a diagnostic value for selected subjects, such as females, cannot be excluded.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 052269582

Download citation: RISBibTeXText

PMID: 21067843

DOI: 10.1016/j.lungcan.2010.10.005

Related references

Combined CADM1 and MAL promoter methylation analysis to detect (pre-)malignant cervical lesions in high-risk HPV-positive women. International Journal of Cancer 129(9): 2218-2225, 2013

Combined promoter methylation analysis of CADM1 and MAL: an objective triage tool for high-risk human papillomavirus DNA-positive women. Clinical Cancer Research 17(8): 2459-2465, 2011

Promoter methylation of APC and RAR-β genes as prognostic markers in non-small cell lung cancer (NSCLC). Experimental and Molecular Pathology 100(1): 109-113, 2016

Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC). Bmc Cancer 11: 147, 2011

Association of promoter methylation with histologic type and pleural indentation in non-small cell lung cancer (NSCLC). Diagnostic Pathology 6: 48, 2011

CADM1, MAL, and miR124 Promoter Methylation as Biomarkers of Transforming Cervical Intrapithelial Lesions. International Journal of Molecular Sciences 20(9), 2019

Detection of methylation of the promoter region of the MAL and CADM1 genes by pyrosequencing in cervical carcinoma. Neuro Endocrinology Letters 35(7): 619-623, 2015

Associations between RASSF1A promoter methylation and NSCLC: a meta-analysis of published data. Asian Pacific Journal of Cancer Prevention 14(6): 3719-3724, 2014

Association between dense CADM1 promoter methylation and reduced protein expression in high-grade CIN and cervical SCC. Journal of Pathology 215(4): 388-397, 2008

Aberrant methylation of the CADM1 promoter is associated with poor prognosis in hepatocellular carcinoma treated with liver transplantation. Oncology Reports 25(4): 1053-1062, 2011

Methylation of CADM1 and MAL together with HPV status in cytological cervical specimens serves an important role in the progression of cervical intraepithelial neoplasia. Oncology Letters 16(6): 7166-7174, 2018

CADM1 and MAL promoter methylation levels in hrHPV-positive cervical scrapes increase proportional to degree and duration of underlying cervical disease. International Journal of Cancer 133(6): 1293-1299, 2013

Maspin expression in normal lung and non-small-cell lung cancers: cellular property-associated expression under the control of promoter DNA methylation. Oncogene 23(23): 4041-4049, May 20, 2004

Expression analysis of EML4 in normal lung tissue and non-small cell lung cancer (NSCLC) in the absence and presence of chemotherapeutics. Romanian Journal of Morphology and Embryology 51(4): 647-653, 2011

Performance of CADM1/MAL-methylation analysis for monitoring of women treated for high-grade CIN. Gynecologic Oncology 143(1): 135-142, 2017